Violation Tracker Agency Summary Page
Agency Name:
Multistate Attorneys General Case
Penalty Total since 2000:
$111,395,268,927
Number of Records:
680
Note:
The penalty total above and the parent totals below include some cases in which both a state and a federal agency were involved and issued separate announcements of the outcome. The individual penalty records below marked by an asterisk are ones for which Violation Tracker contains a separate federal entry.
| Top 10 Parent Companies | Total Penalty $ | Number of Records |
|---|---|---|
| Bank of America | $26,114,848,408 | 10 |
| UBS | $11,393,380,000 | 5 |
| Citigroup | $8,235,591,577 | 7 |
| JPMorgan Chase | $6,208,338,661 | 10 |
| BP | $4,910,000,000 | 2 |
| American Electric Power | $4,687,500,000 | 3 |
| Morgan Stanley | $4,060,100,000 | 4 |
| Goldman Sachs | $3,690,833,333 | 3 |
| Deutsche Bank | $3,648,333,333 | 3 |
| Wells Fargo | $1,872,683,716 | 8 |
Individual Penalty Records:
Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
| Company | Parent | Parent Major Industry | Primary Offense Type | Year |
Penalty Amount |
|---|---|---|---|---|---|
| AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | (*) $46,500,000 |
| Hynix Semiconductor, Inc. | SK Holdings | electrical and electronic equipment | price-fixing or anti-competitive practices | 2010 | $49,971,842 |
| Bridgestone/Firestone, Inc. | Bridgestone | automotive parts | consumer protection violation | 2001 | $51,500,000 |
| Ford Motor Company | Ford Motor | motor vehicles | motor vehicle safety violation | 2002 | $51,500,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $55,000,000 |
| House of Prince A/S | tobacco litigation | 2006 | $55,400,000 | ||
| Merck & Co. | Merck | pharmaceuticals | consumer protection violation | 2008 | $58,000,000 |
| Wachovia Bank N.A. | Wells Fargo | financial services | price-fixing or anti-competitive practices | 2011 | (*) $58,750,000 |
| HSBC | HSBC | financial services | mortgage abuses | 2016 | (*) $59,500,000 |
| First Alliance Mortgage Company | mortgage abuses | 2002 | $60,000,000 | ||
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | False Claims Act and related | 2010 | (*) $60,000,000 |
| Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | $60,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $60,000,000 |
| Wachovia Securities | Wells Fargo | financial services | investor protection violation | 2008 | $60,000,000 |
| C.R. Bard, Inc. | Becton Dickinson | medical equipment and supplies | drug or medical equipment safety violation | 2020 | $60,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $62,000,000 |
| BASF Corporation | BASF | chemicals | price-fixing or anti-competitive practices | 2000 | $62,258,250 |
| Micron Technology, Inc. | Micron Technology | electrical and electronic equipment | price-fixing or anti-competitive practices | 2010 | $66,774,984 |
| Bank of America | Bank of America | financial services | price-fixing or anti-competitive practices | 2010 | (*) $67,000,000 |
| UBS AG | UBS | financial services | interest rate benchmark manipulation | 2018 | $68,000,000 |
| AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | $68,500,000 |
| Walgreens Boots Alliance | Walgreens Boots Alliance | retailing | False Claims Act and related | 2019 | (*) $69,200,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2006 | $70,000,000 |
| Watson Pharmaceuticals | AbbVie | pharmaceuticals | False Claims Act and related | 2011 | $70,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | $71,000,000 |
| Fiat Chrysler | Stellantis | motor vehicles | environmental violation | 2019 | $72,500,000 |
| JPMorgan Chase | JPMorgan Chase | financial services | price-fixing or anti-competitive practices | 2011 | (*) $75,000,000 |
| Cancer Fund of America Inc. | consumer protection violation | 2016 | $75,800,000 | ||
| St. Paul Travelers | Travelers | financial services | price-fixing or anti-competitive practices | 2006 | $77,000,000 |
| ACE, Ltd | Chubb Limited | financial services | price-fixing or anti-competitive practices | 2006 | $80,000,000 |
| Bear Stearns & Co. LLC | JPMorgan Chase | financial services | investor protection violation | 2002 | (*) $80,000,000 |
| Deutsche Bank | Deutsche Bank | financial services | investor protection violation | 2002 | $80,000,000 |
| J.P. Morgan Chase & Co. | JPMorgan Chase | financial services | investor protection violation | 2002 | (*) $80,000,000 |
| Lehman Brothers Inc. | Lehman Brothers | financial services | investor protection violation | 2002 | (*) $80,000,000 |
| UBS Warburg LLC | UBS | financial services | investor protection violation | 2002 | (*) $80,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | (*) $83,129,754 |
| American Honda Motor Co. Inc. and Honda of America Mfg. Inc. | Honda | motor vehicles | consumer protection violation | 2020 | $85,140,000 |
| Nationstar Mortgage dba Mr. Cooper | Mr. Cooper Group | financial services | consumer protection violation | 2020 | (*) $86,300,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*) $88,258,694 |
| GlaxoSmithKline LLC | GlaxoSmithKline | pharmaceuticals | drug or medical equipment safety violation | 2012 | $90,000,000 |
| Penguin Group (USA) Inc. | Bertelsmann | media | price-fixing or anti-competitive practices | 2014 | $90,000,000 |
| Samsung Semiconductor, Inc. and Samsung Electronics Company, Ltd. | Samsung | diversified | price-fixing or anti-competitive practices | 2007 | $90,000,000 |
| UBS AG | UBS | financial services | price-fixing or anti-competitive practices | 2011 | (*) $90,800,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | (*) $91,602,000 |
| Colfax Capital Corporation and Culver Capital, LLC, also collectively known as Rome Finance | consumer protection violation | 2014 | (*) $92,000,000 | ||
| Western Union Financial Services, Inc. | Western Union | financial services | anti-money-laundering deficiencies | 2010 | $94,000,000 |
| Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*) $95,000,000 |
| USA Discounters | consumer protection violation | 2016 | $95,900,000 | ||
| Robert Bosch | Robert Bosch | automotive parts | environmental violation | 2019 | $98,700,000 |
| AmerisourceBergen Corporation | AmerisourceBergen | wholesalers | drug or medical equipment safety violation | 2018 | (*) $99,875,000 |
| Barclays Bank PLC | Barclays | financial services | interest rate benchmark manipulation | 2016 | $100,000,000 |
| Bristol-Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | $100,000,000 |
| Citibank | Citigroup | financial services | interest rate benchmark manipulation | 2018 | $100,000,000 |
| Mallinckrodt plc | Mallinckrodt | pharmaceuticals | price-fixing or anti-competitive practices | 2017 | (*) $100,000,000 |
| Merrill Lynch & Co. Inc. | Bank of America | financial services | investor protection violation | 2002 | (*) $100,000,000 |
| Novartis Pharmaceuticals Corp. | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | $103,000,000 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | pharmaceuticals | kickbacks and bribery | 2014 | $105,000,000 |
| Chase Bank USA N.A. | JPMorgan Chase | financial services | consumer protection violation | 2015 | (*) $106,000,000 |
| Bayer AG | Bayer | chemicals | False Claims Act and related | 2003 | (*) $108,000,000 |
| Mylan Laboratories et al. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | (*) $108,000,000 |
| Ally Financial | Ally Financial | financial services | mortgage abuses | 2012 | (*) $109,628,425 |
| Goldman Sachs | Goldman Sachs | financial services | investor protection violation | 2002 | (*) $110,000,000 |
| Chimei Innolux Corp. | Chi Mei Corporation | chemicals | price-fixing or anti-competitive practices | 2011 | $110,273,318 |
| Student Loan Xpress, Inc. | CIT | financial services | consumer protection violation | 2009 | $112,825,000 |
| Apple Inc. | Apple Inc. | electrical and electronic equipment | consumer protection violation | 2020 | $113,000,000 |
| Hartford Financial Services Group, Inc. | Hartford Financial Services | financial services | price-fixing or anti-competitive practices | 2007 | $115,000,000 |
| Strong Capital Management Co. | Wells Fargo | financial services | investor protection violation | 2004 | (*) $115,000,000 |
| Sharp Corporation | Foxconn Technology Group (Hon Hai Precision Industry Company) | electrical and electronic equipment | price-fixing or anti-competitive practices | 2011 | $115,500,000 |
| Cephalon Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | (*) $116,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2019 | $116,860,000 |
| UHS, Inc and UHS of Delaware, Inc. | Universal Health Services Inc. | healthcare services | False Claims Act and related | 2020 | (*) $117,000,000 |
| Mylan Pharmaceuticals, Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2009 | (*) $118,000,000 |
| Practice Fusion, Inc. | Allscripts Healthcare Solutions | information technology | kickbacks and bribery | 2020 | (*) $118,600,000 |
| General Motors Company | General Motors | motor vehicles | motor vehicle safety violation | 2017 | $120,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2019 | $120,000,000 |
| Lender Processing Services, Inc. | Fidelity National Financial | financial services | mortgage abuses | 2013 | $120,000,000 |
| Maxim Healthcare Services, Inc. | Maxim Healthcare Services | miscellaneous services | False Claims Act and related | 2011 | (*) $121,514,199 |
| Tenet Healthcare Corporation | Tenet Healthcare | healthcare services | kickbacks and bribery | 2016 | (*) $123,772,464 |
| King Pharmaceuticals | Pfizer | pharmaceuticals | False Claims Act and related | 2006 | (*) $124,000,000 |
| AIM Advisors | Invesco | financial services | investor protection violation | 2004 | (*) $125,000,000 |
| Cephalon | Teva Pharmaceutical Industries | pharmaceuticals | consumer protection violation | 2016 | $125,000,000 |
| Morgan Stanley | Morgan Stanley | financial services | investor protection violation | 2002 | (*) $125,000,000 |
| Ocwen Financial Services | Ocwen Financial | financial services | mortgage abuses | 2013 | (*) $127,300,000 |
| WellCare Health Plans Inc. | Centene | healthcare services | False Claims Act and related | 2012 | (*) $137,500,000 |
| Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | $142,494,000 |
| Pershing Square Capital Management | investor protection violation | 2017 | $145,000,000 | ||
| Valeant Pharmaceuticals International, Inc. | Bausch Health | pharmaceuticals | investor protection violation | 2017 | $145,000,000 |
| Uber Technologies | Uber Technologies | miscellaneous services | consumer protection violation | 2018 | $148,000,000 |
| Brown & Williamson Tobacco | British American Tobacco | tobacco | tobacco litigation | 2003 | $150,000,000 |
| JPMorgan Chase | JPMorgan Chase | financial services | investor protection violation | 2015 | $150,000,000 |
| McKesson Corporation | McKesson | wholesalers | False Claims Act and related | 2012 | $151,000,000 |
| Par Pharmaceuticals, Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2011 | $154,000,000 |
| Volkswagen AG | Volkswagen | motor vehicles | environmental violation | 2017 | $157,000,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | pharmaceuticals | False Claims Act and related | 2007 | (*) $160,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | pharmaceuticals | drug or medical equipment safety violation | 2010 | (*) $163,560,000 |
| Student CU Connect CUSO, LLC | consumer protection violation | 2019 | (*) $168,000,000 | ||
| Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2010 | $169,000,000 |
| AU Optronics Corporation | AU Optronics | electrical and electronic equipment | price-fixing or anti-competitive practices | 2012 | $170,000,000 |
| Zurich American Insurance Company | Zurich Insurance | financial services | price-fixing or anti-competitive practices | 2006 | $171,700,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*) $173,000,000 |
| Equifax | Equifax | miscellaneous services | privacy violation | 2019 | $175,000,000 |
